Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Partner

Brief description/objective

Canakinumab for the prevention of recurrences after electrical cardioversion in patients with persistent atrial fibrillation
(CONVERT-AF) trial

Primary objective:
To determine the effect of canakinumab on atrial fibrillation (AF) recurrences within 6 months after electrical cardioversion in patients with persistent AF

Secondary objectives:
To determine the effect of canakinumab on
- Recurrences of documented AF within 1 month after cardioversion
- Recurrences of documented AF within 3 months after cardioversion
- Time to first redo cardioversion
- Use of antiarrhythmic drugs (Vaughan Williams class 1 or 3) at 6 m
- Survival free of unplanned hospitalizations
- Change in CRP levels from randomization to 6 months